Prodrugs offer a versatile strategy to overcome flaws of viable drug candidates or clinically approved drugs. However, the strategic importance of prodrugs in the pharmaceutical industry has often been challenged, and prodrugs are often considered as the last option after lead optimization and when the selected drug candidate has faced significant pharmaceutical and pharmacokinetic limitations. Based on recent success in marketed drugs, prodrug strategy should clearly be considered already in early stages of lead optimization. During the past five years or so, prodrugs have accounted for about 10% of all small molecular weight drugs that have come to the market. In 2015 alone, the FDA approved seven prodrugs, which gives a prodrug prevalence of over 20% among the small molecules or over 15% among the total amount of the FDA approved drugs that year. A great number of various prodrugs are also undergoing late stage clinical trials. The pharmaceutical industry will therefore continue to depend on prodrugs for the foreseeable future. In this review, we will present the state of the art in the design of the prodrugs launched by the FDA since 2015. We will also provide an overview of some interesting late stage clinical prodrug candidates. We hope this review will demonstrate potential of prodrug strategies and facilitates the use of prodrugs in drug discovery projects.
Introduction
There are many benefits of using prodrug strategies. Prodrugs can offer a versatile strategy to improve suboptimal pharmaceutical and pharmacokinetic properties, efficacy or safety profile of viable drug candidates and in some cases even clinically approved drugs (Huttunen et al., 2011; Rautio et al., 2008; Stella, 2010; Clas et al., 2014) . However, substantial amount of resources have been traditionally spent on structure-activity optimization and formulation approaches to address those daunting limitations. Many times, the prodrug strategy can, however, represent a comparable smaller challenge and be more feasible than the alternative of searching for a new candidate with optimal properties or of taking formulation approaches of heroic proportions. Therefore, the prodrug strategy should be considered in early stages of lead optimization and run in parallel with other approaches (Anderson, 1985) .
This change in paradigm has clearly received some attention recently because several recent drugs reaching the market employed prodrug strategies. Between a five-year period, 2010 and 2014, the FDA approved 127 small molecular weight drugs. Of these, 13, or 10.2%, can clearly be identified as prodrugs (Table 1) . More recently, in 2015, the FDA approved 45 new drugs, of which small molecular weight drugs accounted for 32 drugs. Of these 32 small molecules seven can be clearly identified as prodrugs (Table 2 ). This gives a prodrug prevalence of over 20% among the small molecules or over 15% among the total amount of the FDA approved drugs in 2015. This is close to another peak year of prodrugs. In 2008, eight prodrugs were approved which made up 33% of all approved small molecular weight drugs. No prodrugs were launched in 2016 but telotristat etiprate (ethyl ester) for the treatment of carcinoid syndrome was approved in February 2017. It has been estimated that currently approximately 10% of all drug worldwide can be classified as prodrugs (Huttunen et al., 2011; Rautio, 2011) .
In this review, we will focus on the most recent prodrugs, in particular on those that have been able to cross the approval threshold since 2015. These eight prodrugs are aripiprazole lauroxil, isavuconazonium sulfate, ixazomib citrate, sacubitril, selexipag, tenofovir alafenamide sulfate, uridine triacetate, and telotristat etiprate with their respective metabolites aripiprazole, isavuconazole, ixazomib, LBQ657, ACT-333679, tenofovir, uridine, and telotristat being pharmacologically active (Table 2) (Mullard, 2016) . Five of the active compounds are newly approved chemical entities -isavuconazole, ixazomib, sacubitril metabolite LBQ657, selexipag metabolite ACT-333679, and telotristat, while the rest had their active compounds approved earlier. There are also a number of new prodrugs currently in various stages of clinical trials. We have selected some of the interesting examples for more detailed inspection in this review. 
Prodrugs launched since 2015
Since 2015 the FDA has approved eight new prodrugs (Table 2) . From a prodrug design point of view, most of the recently launched prodrugs utilize well-known and previously thoroughly explored prodrug strategies. On the other hand, year 2015 introduced also two novel prodrug strategies, which have not appeared in any previously approved prodrug. First, isavuconazonium utilizes a water-soluble triazolium salt type of prodrug in which a sarcosine ester functions as the solubilizing group and as the enzymatically labile trigger to release a spontaneously and rapidly degradable self-immolative linker, and consequently isavuconazole. Secondly, little attention has so far been paid to the possibility that N-acylsulfonamides are hydrolyzed to the corresponding carboxylic acids in vitro and in vivo. In selexipag, prolonged exposure to the potent carboxylic acid form is provided by the N-acylsulfonamide prodrug, which is slowly converted to the carboxylic acid in vivo. Both isavuconazonium and selexipag will be discussed in more detailed manner below along with the other prodrugs approved since 2015.
Isavuconazonium sulfate (Cresemba®)
Isavuconazonium sulfate was the first prodrug, which was granted approval by the FDA in 2015. It is a water-soluble prodrug of isavuconazole, that is a second-generation triazole and the first antifungal specifically indicated for treatment of invasive aspergillosis and invasive mucormycosis in adults (Walker et al., 2016) . Isavuconazole possesses a core structure very similar to that of other triazoles including triazole and difluorobenzene groups (Scheme 1). Isavuconazole has also a thiazolyl-benzonitrile side chain. Due to these aromatic moieties, isavuconazole possesses low solubility in water, which is a significant barrier to the formulation of intravenous products. Similar challenges hampered the development of other triazoles, such as voriconazole, which requires a beta-cyclodextrin as a solubilizing agent.
In an effort to improve water solubility of isavuconazole, both the tertiary alcohol and the triazole group in isavuconazole were considered as possible synthetic handles for prodrug derivatization (Ohwada et al., 2002; Ohwada et al., 2003) . However, considerable steric hindrance around the hydroxyl group prompted the design of acyloxyalkyl triazolium salt type of prodrugs based on the research of Bogardus and Higuchi (Bogardus and Higuchi, 1982) . The general prodrug concept is illustrated in Scheme 1. A representative prodrug 1 contains an alkyl carbonyl ester group, which can be rapidly hydrolyzed by nonspecific plasma esterases to generate an unstable alcohol intermediate, which subsequently undergoes a spontaneous intra-molecular cyclization and N-dealkylation to release isavuconazole, a cyclic carbamate and formaldehyde.
In in vitro studies in rat plasma compound 1 and its alkyl carbonyl ester analogs were all rapidly hydrolyzed to give corresponding primary hydroxyl alkyl derivatives. However, these intermediates were slowly converted to isavuconazole having half-lives in hours. Moreover, these compounds all showed < 1 mg/ml solubility in water. Consequently, a series of aromatic analogs of 1 having a solubilizing sarcosine group were synthesized with the aim of increased conversion rate and water solubility. Especially the sarcosine ester 2, having a 2-aminopyridine ring as an aromatic and electron withdrawing structure, was rapidly converted into isavuconazole in the plasma of various animal species having half-lives < 1 min in rat, monkey and human, and with no detection of intermediate (Scheme 2). This prodrug also exhibited very good solubility in water (over 100 mg/ml) and reasonable high stability in aqueous buffer solution at pH values ranging from 1 to 4 (> 99% of the prodrug remaining after 7 h) both being requisites for parenteral use. In further preclinical studies, the prodrug 2 showed relative bioavailability of 62% and 87% in rats and monkeys, respectively, after oral administration.
The prodrug, isavuconazonium sulfate (2), is now available in humans in both oral capsules and lyophilized powder for reconstitution with water for intravenous administration for once-a-day dosing. After oral administration, no significant concentrations of the prodrug or inactive cleavage product can be detected in the plasma, suggesting a rapid presystemic conversion of isavuconazonium in the intestinal tract and/or liver as well as plasma. Isavuconazonium produces maximum plasma concentrations (C max ) of isavuconazole 2-3 h after single and multiple doses (Schmitt-Hoffmann et al., 2006a; Schmitt-Hoffmann et al., 2006b) . After intravenous administration, isavuconazonium is quickly hydrolyzed completely by plasma esterases, predominately by butylcholinesterase, to a benzyl alcohol, which undergoes an intramolecular cyclization and N-dealkylation to isavuconazole and an inactive cyclic by-product (also referred to as BAL8728) (Scheme 2). The prodrug was undetectable in plasma by 1.25 h from the start of the 1 h infusion. The total exposures of the prodrug and inactive cleavage product based on AUC were < 1% and 1.3% that of isavuconazole, respectively. Orally administered isavuconazonium effectively delivers isavuconazole, as evidenced by the fact that oral isavuconazole is bioequivalent to the intravenous formulation. The absolute bioavailability of isavuconazole after oral administration of the prodrug is determined to be 98%. In addition to excellent bioavailability, isavuconazole serum concentrations show low inter-subject variability. 
Sacubitril (Entresto®)
A majority of carboxylic acid ester prodrugs on the market are ethyl esters, partly for the reasons that the leaving group ethanol has minimal toxicity and that ethyl esters are usually readily hydrolyzed by ubiquitous esterases. One special therapeutic category of ethyl ester prodrugs is the angiotensin-converting enzyme (ACE) inhibitors, such as enalapril and perindopril, where one of the carboxylic acid groups is masked as an ethyl ester making the prodrug more lipophilic (Beaumont et al., 2003) . Sacubitril (formerly AHU377; Fig. 1 ) is an ethyl ester prodrug of sacubitrilat (LBQ657), which in turn, inhibits the enzyme neprilysin, an endopeptidase that is responsible for the degradation of atrial, brain, and c-type natriuretic peptides (Ruilope et al., 2010) . The inhibition of neprilysin leads to reduced breakdown and increased concentration of these endogenous natriuretic peptides in addition to increased levels of vasoconstricting hormones such as angiotensin II. In addition, sacubitril is co-crystallized, in a one-to-one molar ratio, with valsartan (Entresto®; formerly LCZ696) which blocks angiotensin II receptor type-1 preventing the vasoconstrictive effects. Use of the combination results in a decrease in vascular resistance and blood pressure. Entresto® is the first drug in more than a decade to reduce mortality among heart-failure patients.
Sacubitril was first described in 1995 by Ksander et al. (Ksander et al., 1995) Although no clear reason for using a prodrug strategy was reported, it can be assumed that the aim was to improve lipophilicity of the diacidic sacubitrilat by masking one of its carboxylic acid groups. Ethylation of sacubitrilat increased the clogD 6.5 value from − 1.0 to 1.5 (ChemAxon), which can be considered as a significant increase in lipophilicity. Ethylation also reduced inhibition of human recombinant neprilysin enzyme as sacubitril is a poor inhibitor with in vitro IC 50 value of 16,700 ± 2300 nM while sacubitrilat is a potent inhibitor with IC 50 value of 2.3 ± 0.4 nM.
Sacubitril was predominantly converted to sacubitrilat via esterase catalyzed hydrolysis in liver slices from rat, dog and human (Anon, 2014) . The conversion selectively takes place by hepatic carboxylesterase 1 (CES1) in humans (Shi et al., 2016) . CES1 is highly expressed in the liver and it preferentially hydrolyzes compounds that contain a larger acyl moiety and a smaller alcohol moiety (Imai, 2006) . The ethyl ester hydrolysis of sacubitril was the primary route of metabolism in vivo in all species, as sacubitrilat was the major circulating component in plasma as well as the major radiolabeled component excreted in feces and/or urine after oral administration. However, the hydrolysis showed a significant species difference in conversion rates. The conversion from sacubitril to sacubitrilat was extensive in mouse Scheme 1. Conversion of acyloxyalkyl triazolium salt type of prodrugs.
Scheme 2. Conversion of isavuconazonium to isavuconazole and an inactive cyclic by-product. and rat, which showed 73% and 80% conversion percentages based on the total amounts of both drugs in plasma/blood. In contrast, the rate of conversion was moderate in dog and monkey (sacubitril:sacubitrilat = 34%:46% of AUC in dogs and 37%:62% of AUC in monkeys). On the other hand, bioconversion was extensive in humans and the major compound detected was sacubitrilat (93-98% of AUC comparing to sacubitril) (Anon, 2014) .
In rat studies administration of sacubitril at 30 mg/kg orally resulted in free plasma levels of the released sacubitrilat 10-100 times greater than its inhibitory constant (IC 50 = 5 nM). Similar dosing in cynomolgus monkeys produced free plasma concentrations which were 38-1500 higher than the IC 50 value of sacubitrilat during a 6 hourstudy (Ksander et al., 1995) . In general, sacubitrilat was well and rapidly absorbed in preclinical studies after oral dosing showing absorption ranging from 40% in monkey to 100% in mouse, and T max values ranging between 0.25 and 0.75 h (Anon, 2014) . In human, absorption was estimated to be at least 60%. Bioavailability of the active sacubitrilat was moderate to high (monkey 41%, rat 72%, dog 77%, and mouse 100%) after oral dosing and it was estimated to be higher than 50% in human. In Caco-2 cell monolayer transport experiments apicalto-basolateral permeability of sacubitril was over 30 times higher than that of sacubitrilat (23-28 × 10 − 5 cm/min vs 0.67-0.75 × 10 − 5 cm/ min) which would classify sacubitril as a moderately highly permeable drug substance and is consistent with the good absorption observed in various species (Anon, 2014) .
Uridine triacetate (Xuriden®)
Uridine triacetate was granted FDA approval for two separate indications in 2015. First approval was granted for the treatment of hereditary orotic aciduria (Xuriden®), an ultra-orphan indication that has been reported in only 20 people worldwide. Later in 2015 uridine triacetate was approved for the emergency treatment of fluorouracil or capecitabine overdose or toxicity (Vistogard®).
Uridine, a naturally occurring pyrimidine nucleoside, is a highly hydrophilic compound having clogP value of −2.4 (ChemAxon). Therefore, its oral absorption is via facilitated diffusion or specific uridine transporters (Pizzorno et al., 2002) resulting in a poor oral bioavailability of < 10% in humans (van Groeningen et al., 1991) . Dose-limiting side-effects such as diarrhea limit the use of large doses. Uridine triacetate (formerly PN401) is an O-acetylated form of uridine (Fig. 2) . It is more lipophilic (clogP = −1.1; ChemAxon) than uridine, it does not require transporters for oral absorption and it is reabsorbed from the renal tubules better that uridine (von Borstel and Bamat, 1989) . The triacetylated prodrug and its mono-and diester metabolites are also resistant to catabolism by hepatic uridine phosphorylase which effectively metabolizes circulating uridine (Ashour et al., 1996) . In preclinical studies, plasma levels of uridine were significantly (5-to 10-fold) higher following orally dosed uridine triacetate than after an equimolar dose of uridine in mice and rats (von Borstel and Bamat, 1989; Ashour et al., 1996) . In humans, the prodrug has been shown to deliver 4-to 6-fold more uridine into the body compared to uridine itself (Weinberg et al., 2011; Ison et al., 2016) . The highest uridine plasma concentrations following oral prodrug dose are generally achieved within 2 to 3 h, and the half-life ranges from approximately 2 to 2.5 h.
Following oral administration, uridine triacetate is deacetylated by yet unidentified nonspecific esterases throughout the body, yielding uridine and acetate in the circulation. While no detailed mechanism for bioconversion is reported, the conversion is likely to take place via diand monoester intermediates as depicted in Fig. 2 (Ashour et al., 1996) . From prodrug design point of view, uridine triacetate resembles famciclovir that is a diacetate and 6-deoxy prodrug of penciclovir. The majority of famciclovir is absorbed intact and the hydrolysis of the first acetate group takes place by esterases in the intestinal cells after absorption. Formation of 6-deoxy penciclovir and penciclovir has been shown to occur mainly in the liver (Gudmundson and Antman, 2007) . This observation is in line with CES expression and substrate specificity. CES2 is the main form present in the intestine and it predominantly hydrolyses compounds with large alcohol and small acyl groups such as famciclovir and uridine triacetate (Imai, 2006) .
Both uridine triacetate and famciclovir are good examples that increasing the lipophilicity by masking polar hydroxyl groups by esterification can result in an orally bioavailable prodrug.
Aripiprazole lauroxil (Aristada®)
Aripiprazole is approved for various psychiatric disorders and marketed in several dosage formulations. The mechanism of action of aripiprazole is unknown, but its efficacy may be mediated through a combination of partial agonist activity at D 2 and 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors (Meltzer et al., 2015) . In October 2015, the FDA approved aripiprazole lauroxil for the treatment of adults with schizophrenia. Aripiprazole lauroxil is intended for intramuscular injection and can be administered every 4 weeks or every 6 weeks, depending on the dose and the location of injection.
Aripiprazole lauroxil is a lipophilic N-acyloxymethyl prodrug of aripiprazole (Fig. 3) . Its lipophilicity is several thousand fold higher than that of already reasonable lipophilic aripiprazole (clogD 7.4 increases from 4.6 to 9.0, ChemAxon). These type of higher alkyl chain fatty acid esters have traditionally been utilized in prodrug design to prolong action of hydroxyl group containing drugs after intramuscular administration (Rautio and Laine, 2017) . Because aripiprazole has no hydroxyl group to be esterified, this prodrug utilizes the N-acyloxymethyl strategy in which dodecanoic acid (i.e., lauric acid) has been used to acylate the N-hydroxymethyl group formed from the reaction of formaldehyde with the NH-acidic amide in the structure of aripiprazole. J. Rautio et al. European Journal of Pharmaceutical Sciences 109 (2017) 146-161 The commonly used fatty acid esters in these type of prodrugs are decanoates, palmitates, enanthates, cypionates, or valerates (Rautio and Laine, 2017) . These highly lipophilic prodrugs are typically formulated in an oil vehicle and are slowly released in the systemic circulation from the site of injection resulting in sustained-release plasma levels of 2-8 weeks. The solubilizing ingredients in aripiprazole lauroxil suspension include sorbitan monolaurate and polysorbate 20. Systemic absorption of aripiprazole following single intramuscular injection occurs within five to six days and continues for an additional 36 days (Anon, n.d.) . Before aripiprazole lauroxil, this fatty-acid prodrug strategy has resulted in several marketed sustained-release injectables of, for example, estrogens (e.g., estradiol), neuroleptics (e.g., fluphanazine, flupentixol, haloperidol, pipotiazine, zuclopenthixol), contraceptives (e.g., hydroxyprogesterone, norethisterone), and anabolics (e.g., nandrolone, testosterone) (Rautio and Laine, 2017) .
Aripiprazole lauroxil is a prodrug that, once injected into the body, undergoes several steps to yield aripiprazole (Fig. 3) . In general, bioconversion of N-acyloxyalkyl derivatives of NH-acidic compounds is described to proceed through a two-step hydrolytical process. Esterasemediated hydrolysis of the acyl moiety produces first an N-hydroxyalkyl intermediate, which subsequently undergoes spontaneous nonenzymatic conversion to release the parent NH-acid and an aldehyde, in this case formaldehyde. The pK a value of NH-acid has been reported to influence on the rate of chemical conversion of the N-hydroxyalkyl intermediate with the more acidic parent drug giving the fastest conversion (Johansen and Bundgaard, 1979; Bundgaard and Johansen, 1980) . For the N-hydroxymethyl form, a conversion half-life at pH 7.4 is < 1 h if the pK a of the NH-acid is < 13. Aripiprazole has a pK a value of 13.5 for its NH-acidic amide (Anon, n.d.) and, therefore, its conversion half-life in aqueous solution should be > 1 h. However, in the recent in vitro studies in a phosphate buffer solution of pH 7.4 and at 25°C the N-hydroxymethyl aripiprazole had a half-life of approximately 35 min, and a much faster conversion rate at 37°C (Rohde et al., 2014) . The faster than predicted conversion may be a reflection of a different chemical space used to make earlier correlations or that the pK a value found in the literature may differ from the actual value of aripiprazole. In in vivo studies in rats, all three forms of aripiprazole were observed after tail vein injection of the prodrug aripiprazole lauroxil, therefore confirming that the bioconversion mechanism of this N-acyloxymethyl prodrug involves the formation of an intermediate Nhydroxymethyl form before releasing the parent drug aripiprazole.
Many of the N-acyloxyalkyl prodrugs from amide-type NH-acids have been shown to degrade via alternative routes (Bundgaard and Nielsen, 1987; Bundgaard and Rasmussen, 1991) . The first route begins with an E1cB elimination reaction creating a carboxylate and an Nacylimine which in the presence of water degrades to produce the Nhydroxyalkyl intermediate. Subsequent elimination of the anion of the parent NH-acid from the intermediate then occurs. The second route involves an SN1 like reaction creating a carboxylic acid anion and an acyliminium cation. Water is added to the acyliminium cation to give a N-hydroxyalkyl intermediate which undergoes elimination of the anion of the parent NH-acid. These alternative degradation routes have resulted in unexpected poor aqueous stability of some N-acyloxyalkyl prodrugs at slightly acidic and neutral pH values, and should be taken into account especially in designing parenteral formulations of N-acyloxyalkyl prodrugs.
Tenofovir alafenamide (Genoya®)
Tenofovir (PMPA) is an acyclic nucleotide analog of dAMP (Fig. 4) that is sequentially phosphorylated in cells by AMP kinase and nucleoside diphosphate kinase to the active species, tenofovir diphosphate, which inhibits the human immunodeficiency virus (HIV) reverse transcriptase (Lee et al., 2005) . The presence of a phosphonate group in tenofovir has two advantages. First, tenofovir circumvents the need for the initial phosphorylation step by host kinases which can be rate limiting for the activation of nucleoside analog inhibitors. Secondly, the phosphonate group is stable to dephosphorylation by ubiquitous plasma phosphatases. The phosphonate group in tenofovir is acidic (pK a 1 = 2, pK a 2 = 6.8) and it exists as a dianionic at most physiological pH values, making tenofovir very polar and having clogP 6.5 −3.5 (ChemAxon). This polar nature of tenofovir limits its cellular permeability and precludes oral absorption (Cundy et al., 1998) .
The first approach to improving the oral bioavailability of tenofovir used acyloxyalkyl esters of the phosphonate functional group. Tenofovir disoproxil fumarate (Viread®) is a bis-isopropyloxycarbonyloxymethyl ester prodrug of tenofovir that was launched in 2001 for the treatment of HIV infections (Fig. 4) . Due to better lipophilicity (logD is 1.25 at 6.5; Viread prescribing information or clogP 6.5 is 2.7; ChemAxon), the prodrug provides dose-proportional pharmacokinetics and oral bioavailability of around 25% in the fasted state (Anon, 2016) . Tenofovir disoproxil was designed to undergo rapid bioconversion to tenofovir after oral absorption. A cascade of conversion mechanisms is initiated by rapid enzymatic hydrolysis of bis-ester by non-specific carboxylesterases in the plasma and the liver (Fardis and Oliyai, 2007) . However, regardless of the remarkable increase in the bioavailability of tenofovir affected by the disoproxil promoiety, the rapid conversion of tenofovir disoproxil to polar tenofovir limits its efficient uptake into target cells and causes its accumulation in the kidney proximal tubules.
Investigations to develop more stable prodrugs which would be selectively hydrolyzed inside target cells to antiviral nucleotides led to the design of tenofovir alafenamide (GS-7340; Fig. 4 ) that was first described almost simultaneously by Ballatore et al. and Eisenberg et al. in 2001 (Ballatore et al., 2001; Eisenberg et al., 2001) . Tenofovir alafenamide is a lipophilic (clogP 6.5 = 1.9; ChemAxon) aryloxy phosphoramidate prodrug of tenofovir in which phenol and an esterified amino acid moiety, alanine, are used as masking groups of the phosphonate functional group. Therefore, tenofovir alafenamide shows structural similarity with a class of nucleoside monophosphate prodrugs which are referred to as phosphoramidate aryloxy pronucleotides (McGuigan et al., 1998a; McGuigan et al., 1998b) . The very same prodrug strategy is also present in sofosbuvir (Sovaldi) that was launched in 2013 as the first orally effective drug for the treatment of hepatitis C infection (Sofia et al., 2010; Gentile et al., 2015) . Also the majority of nucleotide prodrugs undergoing clinical trials employ the phosphoramidate prodrug strategy.
The activation pathway of tenofovir alafenamide involves multiple enzymes (Scheme 3) (Birkus et al., 2008; Mehellou et al., 2009 ). Interestingly, the promoieties of tenofovir alafenamide can be viewed as a structural analog of Phe-Ala-Ala tripeptide, and therefore, multiple lysosomal serine proteases, such as cathepsin A, are capable of initial hydrolysis of the carboxyester bond (Birkus et al., 2008; Birkus et al., 2007; Birkus et al., 2016) . Intracellular hydrolysis of the ester is followed by a putative nucleophilic attack on the phosphorus by the negatively charged carboxyl group, resulting in the spontaneous elimination of phenol, producing a highly unstable five-membered ring. A nucleophilic attack from a water molecule opens up this heterocyclic ring leading to the generation of a phosphoramidate intermediate. Conversion of the tenofovir alanine intermediate takes place spontaneously in acidic pH of lysosomes leading to the release of the nucleotide analog, tenofovir (Birkus et al., 2016; Birkus et al., 2011) . Because of markedly enhanced stability in plasma compared with tenofovir disoproxil (Eisenberg et al., 2001 ), tenofovir alafenamide results in an increased accumulation of parent tenofovir and its active diphosphate metabolite in peripheral blood mononuclear cells (PBMCs) relative to tenofovir disoproxil after oral administration (Lee et al., 2005) . Tenofovir alafenamide also increases the accumulation of tenofovir in lymphatic tissues, which is likely to favorably affect the therapeutic efficacy of this novel prodrug (Lee et al., 2005) .
The results of clinical studies showed that the administration of 25 mg tenofovir alafenamide shows similar efficacy but less incidence of adverse side-effects than 300 mg dose of tenofovir disoproxil. Three combination products containing tenofovir alafenamide have been approved by the FDA for the management of HIV-1 infection. It is also being pursued as a possible treatment for hepatitis B virus (Murakami et al., 2015) .
The success of both tenofovir alafenamide and sofosbuvir highlights the potential of aryloxy phosphoramidate prodrugs of parent drugs containing phosphonate and phosphate functional groups, respectively, to mask polar, highly ionized functional groups and increase their bioavailability.
Ixazomib citrate (Ninlaro®)
Ixazomib citrate (formerly known MLN9708) is the first oral reversible proteasome inhibitor for the treatment of multiple myeloma (MM) introduced into the market. MM is a form of blood cancer that occurs in infection-fighting plasma cells found in the bone marrow, and that affects two to three people per 100,000. The approval of the firstin-class proteasome inhibitor bortezomib (Velcade®) in 2003 validated the proteasome as a therapeutic target for the treatment of MM. However, development of resistance, side effects and invasive dosing regimens prompted the development of structurally different second generation proteasome inhibitors such as ixazomib citrate (GarciaGomez et al., 2014) .
Ixazomib citrate was selected from a broad range of small-molecule boron-containing proteasome inhibitors which were characterized by improved pharmacokinetic and pharmacodynamic profiles compared with bortezomib (Kupperman et al., 2010) . Ixazomib exists in a citrate ester form, ixazomib citrate, which is hydrolyzed rapidly to release the biologically active boronic acid form, ixazomib (Fig. 5) . Ixazomib itself is an N-capped dipeptidyl leucine boronic acid like bortezomib, and it is able to inhibit the chymotrypsin-like proteolytic site of the 20S proteasome.
The rational for designing a citrate ester prodrug of ixazomib lies in a surprising prodrug nature of a formulation of bortezomib. When oxidatively unstable bortezomib was formulated as a freeze-dried formulation, it was found to rapidly dissolve on reconstitution and have solubility higher than unformulated bortezomib. Better solubility was caused by in situ formation of boronic acid esters by reaction with bulking agent mannitol during the freeze-drying process (Stella and NtiAddae, 2007) . The increase in the pharmaceutical utility of formulations of oxidatively unstable boronic acid compounds may have been one of the driving forces to develop a citrate ester of ixazomib (Elliott et al., 2009) . In preclinical studies ixazomib citrate was immediately hydrolyzed to ixazomib upon exposure to aqueous solution or plasma.
When ixazomib citrate was added directly into rat, dog or human plasma, only ixazomib could be detected after immediate analysis indicating that the half-lives of hydrolysis are in the order of seconds (Kupperman et al., 2010) . Therefore, the B-O-C(= O)-R mixed anhydride functional group may not require enzymatic assistance and is hydrolyzed chemically analogously to the mechanism in the reference of Marinaro et al. (Marinaro et al., 2012) The newly developed therapy offers advantage of fewer, less serious side effects with the comfort of oral administration. Following oral administration, ixazomib citrate is rapidly absorbed with a median t max of 1 h, and with the absolute bioavailability of 58%.
Selexipag (Uptravi®)
Oral selexipag was approved in December 2015 by the FDA for the treatment of pulmonary arterial hypertension (PAH, World Health Organization group I) to delay disease progression and reduce the risk of hospitalization for PAH (Anon, n.d.) . Selexipag is the first medication in its class. It has a similar mode of action to that of endogenous prostacyclin (PGI 2 ), but is a nonprostanoid IP receptor agonist rather than a PGI 2 analogue. Selexipag acts by relaxing muscles in the walls of blood vessels to dilate the vessels and reduce the elevated pressure in vessels supplying blood to the lungs.
Selexipag is a novel N-acylsulfonamide prodrug of its pharmacologically active carboxylic acid form (ACT-333679) (Fig. 6) . Its discovery originated from a study where efforts were directed toward extending the in vivo exposure of a high affinity PGI 2 receptor agonist ACT-333679. With the hope of improved pharmacokinetic properties, the carboxylic acid group of ACT-333679 was replaced by the similarly acidic N-methylsulfonamide group (later selexipag) (Nakamura et al., 2007; Asaki et al., 2015) . While this derivative demonstrated 13-fold lower affinity for PGI 2 receptor than its carboxylic acid analog, it was shown to undergo slow in vitro hydrolysis to the carboxylic acid form by animal and human liver microsomes. The bioconversion in monkey hepatic microsomes was completely inhibited by a serine hydrolase inhibitor, phenylmethylsulfonyl fluoride, indicating that carboxylesterase enzymes are responsible for the hydrolysis. This finding prompted evaluation of additional sulfonamide (1-4) and sulfonylurea (5-6) derivatives (Fig. 6) (Nakamura et al., 2007) . Of those derivatives, which all showed in vitro bioconversion in hepatic microsomes from human and monkey, 1-2 and 5 were selected for in vivo studies with selexipag because of their relatively low hydrolysis rates. In pharmacokinetic studies on monkeys, all compounds underwent bioconversion and released the active carboxylic acid form. In general, the C max values for the active form after oral administration of the prodrugs were approximately 10-30% lower than the C max value observed for ACT-333679 itself. In addition, the apparent terminal half-life (t 1/2 ) of ACT-333679 after oral administration of the prodrugs were 1.5-2.5 times greater. Selexipag showed superior AUC compared with the other derivatives and ACT-333679, and it was selected for further development.
Selexipag is rapidly absorbed after oral administration, showing dose-proportional pharmacokinetics with maximum plasma concentrations of selexipag and ACT-333679 attained within 1-3 and 3-4 h, respectively (Anon, n.d.; Bruderer et al., 2014) . Exposure to selexipag and ACT-333679 is similar in patients with PAH to that in healthy volunteers, with exposure to ACT-333679 about 3-to 4-fold higher than that of selexipag. In comparison with previously developed oral prostacyclins, selexipag has limited adverse effects despite similar or better efficacy.
Telotristat etiprate (Xermelo®)
Telotristat etiprate (LX1032/LX1606 hippurate) is an ethyl ester prodrug of telotristat (LP-778902), an inhibitor of peripheral serotonin synthesis (tryptophan hydroxylase (TPH) inhibition) for the treatment of carcinoid syndrome (Fig. 7) (Kulke et al., 2014) . Telotristat etiprate has received orphan drug designation from European Medicines Agency (EMA) and the FDA for the treatment of carcinoid syndrome not adequately controlled by somatostatin analogues (SSA). Furthermore, FDA approved telotristat etiprate (Xermelo) in February 2017 for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults inadequately controlled by SSA therapy as orally administrated treatment.
From a prodrug design point of view, telotristat etiprate utilizes similar ethyl ester strategy as does sacubitril that was described earlier in this review. The aim of the ethylation of the carboxyl group has likely been to improve the in vivo efficacy of telotristat through increased lipophilicity (clogP 6.5 increases from 2.8 to 5.0; ChemAxon) (Liu et al., 2008) . The conversion of telotristat etiprate to telotristat likely occurs rapidly in vivo, because serotonin levels were found to be reduced throughout the gastrointestinal tract after oral administration of the prodrug in mice (Lapuerta et al., 2015) . In addition, telotristat etiprate has been found in the systemic circulation in only very low levels after J. Rautio et al. European Journal of Pharmaceutical Sciences 109 (2017) 146-161 oral administration in humans (Lapuerta et al., 2015) . Following administration of a single 500 mg dose of telotristat etiprate in healthy subjects, the AUC 0-inf of the intact prodrug was only 0.3% of the AUC 0-inf of telotristat (6.23 ng·hr/ml vs 2320 ng·hr/ml) (Anon, n.d.) .
Examples of prodrugs in clinical trials
Based on the information gathered from the clinical trials database (clinicaltrials.gov) and from pipelines of several biotech companies, a great number of prodrugs are currently undergoing various stages of clinical trials. We will not try to make a comprehensive listing of prodrug candidates in clinical trials, as often candidates are not even described as prodrugs. Instead, some interesting prodrug candidates will be highlighted in the following sections. In these examples, the prodrug technology has been utilized to improve oral absorption by improving aqueous solubility or lipophilicity as well as to achieve site-selective drug delivery, just like in the most marketed prodrug cases.
Phosphate prodrugs for improved aqueous solubility
Phosphate esters are widely used and successful prodrug strategy for addressing poor solubility properties of both orally and parenterally dosed drugs containing hydroxyl and amine groups due to their substantial ionization at the physiological pH values (Stella and Nti-Addae, 2007) . Examples of clinically approved phosphate prodrugs are fosamprenavir (e.g., Lexiva®) and fospropofol (Lusedra®).
Fostemsavir (GSK3684934, formerly BSM-663068) and Debio 1450 (previously AFN-1720) are water-soluble N-phosphonooxymethyl prodrugs of temsavir (GSK2616713, formerly BMS-626529) and Debio 1452 (previously AFN-1252), respectively, that are currently being evaluated in clinical trials (Fig. 8) . Orally administered fostemsavir undergoes rapid and extensive metabolism by alkaline phosphatase on the luminal surface of the small intestine brush border membranes before absorption releasing temsavir most likely via an unstable N-hydroxymethyl intermediate. Due to its higher lipophilicity and good membrane permeability, temsavir is the rapidly absorbed (Nettles et al., 2012; Nowicka-Sans et al., 2012; Regueiro-Ren et al., 2013) . Fostemsavir is in phase 3 trials to evaluate its safety and efficacy in heavily treatment-experienced adults with multi-drug resistant HIV (NCT02362503). It was granted breakthrough therapy designation from the FDA in 2015 for accelerating its development and review.
While fostemsavir is a N-phosphonooxymethyl derivative of a very weakly acidic indole like N-H, Debio 1450 utilizes a similar prodrug strategy for the more acidic imide like N-H in Debio 1452. Possible conversion issues of N-hydroxymethyl intermediates of NH-acids, which were discussed earlier with aripiprazole lauroxil, seem to be no concern with Debio 1450. Debio 1450 was rapidly converted to its active form Debio 1452 with short half-life after intravenous administration in dogs (half-life 0.10 h), and it also resulted in rapid exposure of Debio 1452 in dog plasma after oral administration (Karlowsky et al., 2009; Parsons et al., 2011) . Debio 1450 administrated as intravenous infusion as well as orally has completed phase 2 trial in the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) due to staphylococcus or were sensitive or resistant to methicillin, compared with intravenous vancomycin and oral linezolid (NCT02426918).
Amino acid prodrugs
Amino acid prodrugs have a well-established track of improving solubility and permeability, and consequently, oral delivery of drugs (Vig et al., 2013) . Introducing an amino acid promoiety onto a parent drug can increase the aqueous solubility by several orders of magnitude through an ionized carboxylate anion or ammonium cation. Moreover, improved oral permeability of many prodrugs containing an amino acid promoiety has been attributed to their carrier-mediated transport via intestinal peptide transporter 1 (PEPT1). This characteristic has led to numerous clinical successes already (Beauchamp and Krenitsky, 1993) and there are several interesting amino acids prodrugs in development.
FV-100 is a L-valyl ester prodrug of bicyclic nucleoside analogue Cf1743 (Fig. 9) for the treatment of varicella-zoster virus infection (McGuigan et al., 2007) . Water solubility of Cf1743 with its highly lipophilic pentyl aryl side chain is limited to~0.9 mg/L and this has negative impact on its oral bioavailability that is only~14% in mice. Thus, L-valyl ester prodrug FV-100 was constructed, guided by established valyl ester nucleoside prodrugs valacyclovir and valganciclovir, to overcome the solubility issue. Free valine ester gave a 22-fold improvement in water solubility, and this was further enhanced tens of folds by HCl and succinate salts. As a HCL salt, the L-valyl ester of Cf1743 showed~10-fold boost in oral bioavailability in mice compared to that of Cf1743. FV-100 is entering phase 3 trial (recruiting participants) compared to valacyclovir in subjects with uncomplicated acute herpes zoster (NCT02412917).
BAL101553 is the L-lysine amide prodrug of BAL27862 with improved aqueous solubility, which allows intravenous administration in the absence of solubilizing excipients (Fig. 9) (Prota et al., 2014) . In a first-in-human dose escalation study, the prodrug was shown to be converted upon intravenous administration into the active form, Fig. 7 . Hydrolysis of telotristat etiprate to telotristat. BAL27862. Hydrolytic cleavage of a similar amide bond in lisdexamfetamine is occurring by aminopeptidase-like activity in red blood cell cytosol (Sharman and Pennick, 2014) . BAL27862 is a microtubuletargeting (destabilizing/depolymerizing drug) agent (MTA) inhibiting tumor cell growth and inducing tumor cell death. BAL101553 is going into phase 1/2a trials (recruiting participants) in patients with advanced solid tumors or glioblastoma (or high-grade glioma) and can be administered orally or intravenously (NCT02895360 and NCT02490800).
Brivanib alaninate (BSM-582664) is the L-alanine ester prodrug of brivanib (BSM-540215) (Fig. 9) , an inhibitor of vascular growth factor and fibroblast growth factor receptors (Bhide et al., 2006; Cai et al., 2008) . Rational for discovery of brivanib alaninate was the very low aqueous solubility (< 1 μg/ml at pH 6.5) of brivanib that was believed to contribute its solubility/dissolution rate-limited oral bioavailability in preclinical species, particularly at high doses. The L-alanyl ester prodrug has significantly higher aqueous solubility (73 mg/ml at pH 5.8), which resulted in higher oral bioavailability of brivanib (52-97 in several animal models) (Marathe et al., 2009) . Brivanib alaninate was rapidly hydrolyzed in serum, plasma and liver preparations in vitro. After oral doses of brivanib alaninate to preclinical species, no circulating prodrug was detected, indicating that the prodrug hydrolysis took place presystemically. Phase 2 study of orally administrated brivanib alaninate in patients with persistent or recurrent cervical cancer has been completed (NCT01267253).
Neladenoson bialanate is, from a prodrug design point of view, a novel bis-L-alanyl prodrug of neladenoson (Fig. 9) (Meibom et al., 2017) . Due to low aqueous solubility (e.g. < 0.1 mg/l at pH 4) neladenoson itself shows only low to moderate bioavailability in different species (rat 37%, dog 51%, monkey 39%). Neladenoson bialanate emerged from a series of dipeptide esters of natural and unnatural amino acids. The prodrug is protonated on the terminal amino group under acidic conditions resulting in a solubility of 6 g/l at pH 4.5 from crystalline material. In addition, it shows good stability at pH values lower than 4 as well as rapid liberation of neladenoson in vivo. The oral bioavailability from a suspension of crystalline substance was modestly improved up to 52% in rats. Neladenoson bialanate hydrochloride is currently in PhIIb clinical trials (NCT02992288).
BST-236 (astarabine) is an amino acid prodrug of cytarabine (ara-C) targeted to leukemic blasts/cells (Fig. 9) (Gengrinovitch et al., 2015) .
Cytarabine is the first-line treatment of acute myeloid leukemia (AML) and relapsed acute lymphoblastic leukemia (ALL) with toxic side effects, which significantly limit its use. In its prodrug, cytarabine is linked covalently through the amide bond to aspartic acid. This design is based on the dependence of leukemic cells on external source of asparagine, and its uptake by the cells. After being taken up selectively by leukemia cells, BST-236 is converted to cytarabine that causes the cytotoxic effect. Therefore, the rational for prodrug design in this case is likely targeting. BST-236 is investigated in a phase 1/2a trials administrated as daily intravenous infusion for six consecutive days in patients with AML and ALL (NCT02544438).
Prodrugs for increased lipophilicity and permeability
Adequate lipophilicity is usually requisite for good permeability across biological membranes. Therefore, the permeability across these membranes remains one of the main barriers for polar and charged drugs. Prodrugs with short hydrocarbon promoieties attached to the polar or ionized groups of the hydrophilic parent drug to increase its lipophilicity, and consequently passive diffusion from intestine, has been the most successful area of prodrug research so far. An alternative strategy to increase the oral absorption is to convert the drugs to mimic natural lipids which utilize natural lipid absorption pathways.
Remogliflozin etabonate (RE) is an ethyl carbonate prodrug of remogliflozin (Fig. 10) , and it closely resembles the clinically approved ethyl carbonate ether prodrug of piroxicam, ampiroxicam (e.g. Flucam® in Japan). Remogliflozin is selective inhibitor of renal sodium-dependent glucose transporter-2 (SGLT2) that increases renal glucose excretion for the treatment of type 2 diabetes (Fujimori et al., 2008; Kapur et al., 2013) . RE is absorbed rapidly and almost completely, once in the body, hydrolyzed within enterocytes and hepatocytes to remogliflozin . Phase 2 trial of orally administrated biphasic RE in the treatment of type 2 diabetes has been completed (NCT02537470).
Besifovir (LB80380), an acyclic nucleotide phosphonate (guanosine monophosphate), is a bis-pivaloyloxymethyl (BisPOM) prodrug of LB80331 for the treatment of hepatitis B virus (HBV) infection (Fig. 10) . BisPOM prodrug strategy has been successfully used with the hepatitis B drug, adefovir dipivoxil (Hepsera®). Besifovir is well absorbed and is rapidly converted to the nucleotide LB80331 by the cleavage of the two J. Rautio et al. European Journal of Pharmaceutical Sciences 109 (2017) 146-161 pivaloyl groups in the liver and intestine (deacetylation), subsequent loss of two moles of formaldehyde and finally oxidation (hydroxylation) at the C6 position to LB80317. The triphosphate derivative of LB80317 is the active species (Yuen et al., 2009) . Besifovir is going to phase 3 trial (recruiting participants) compared to tenofovir in chronic hepatitis B patients who have resistance to nucleoside analogues (NCT02792088). Sapacitabine (CS-682 and CYC-682) is a fatty acid amide prodrug of the nucleoside analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC) (Fig. 10) . The lipophilic palmitoyl group on the N4-group of the cytosine enables oral administration and also reduces inactivation by deamination (Hanaoka et al., 1999) . Sapacitabine is metabolized by amidases in plasma, gut and liver to the CNDAC, which is phosphorylated into the active triphosphate form inside the cells before incorporation into cellular DNA generating single-strand breaks. Sapacitabine is in phase 2 trial for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma with deletion of 11q22-23 given in combination with cyclophosphamide and rituximab (NCT01253460).
CMX157 is a liver-targeted lipid conjugate prodrug of tenofovir (TFV/PMPA) (Fig. 10) developed to increase the oral bioavailability and antiviral activity of tenofovir with decreased nephrotoxicity (Painter et al., 2007) . CMX157 is an alkoxyalkyl prodrug that has the hexadecyloxypropyl promoiety attached to one of the hydroxyls on the phosphonate group in tenofovir. The prodrug is designed to disguise TFV as a lysophospholipid and utilize natural lipid (lysolecithin) pathways in its absorption. The release of tenofovir is most likely taking place by phospholipase C, an enzyme that is not present in plasma, thus providing stability for prodrug of this type during oral absorption and transport in plasma to tissues (Hostetler, 2009) . Orally administrated CMX157 is entering phase 2 trials (recruiting participants) in HBV-infected patients (NCT02710604).
Prodrugs for site-selective drug delivery
In general, site-selective drug delivery by prodrug strategies can be attempted either by site-selective prodrug delivery or site-selective prodrug bioconversion.
QGC001 (previously RB150) is a prodrug of specific and selective brain aminopeptidase A (APA) inhibitor EC33 (Fig. 11) , which is a novel centrally acting antihypertensive agent. Intravenously injected EC33 was not able to affect blood pressure in conscious DOCA-salt rats, so a prodrug strategy was introduced to improve its brain penetration (Fournie-Zaluski et al., 2004) . The prodrug is formed by dimerization of EC33 through a disulfide bond and it is able to cross the blood-brain barrier. The disulfide bond of the prodrug can be cleaved by brain reductases to generate EC33 that inhibits brain APA. Orally administrated QGC001 has undergone phase 2 trial in patients with essential hypertension (NCT02322450) and is entering phase 2 trial in heart failure patients (recruiting participants) (NCT02780180).
Zoptarelin doxorubicin (AEZS-108, formerly AN-152) is a cytotoxic peptide prodrug containing cytotoxic doxorubicin linked through a glutaric acid spacer to the luteinizing hormone-releasing hormone (LHRH) agonist D-Lys 6-LHRH which acts as a carrier in targeting tumors overexpressing LHRH receptors (e.g. ovarian, endometrial and breast) (Fig. 11) Nagy et al., 1996) . The prodrug is taken into the target cells in a LHRH receptor-mediated way with little cleavage to doxorubicin in the systemic circulation (Krebs et al., 2000) . Zoptarelin doxorubicin, administrated as intravenous infusion, has just undergone phase 3 trial (no results available yet) for endometrial cancer resistant to platinum/taxane-based chemotherapy (NCT01767155).
Mipsagargin (G202) is a prostate specific memory antigen (PSMA) -activated prodrug of a thapsigargin (TG) analog (Fig. 12) (Denmeade et al., 2003) . TG is an irreversible inhibitor of the sarcoendoplasmic reticulum calcium transport ATPase (SERCA) pump leading to increased cytoplasmic calcium levels and thus, induced apoptosis (Thastrup et al., 1990) . Since TG induces apoptosis in all mammalian cells, a prodrug strategy was utilized to target the cytotoxic activity of TG to tumor tissue. Unique carboxypeptidase activity and restricted expression of the PSMA in the blood vessels of various solid tumors guided the development of a protease-activated prodrug strategy in which a highly potent side chain modified TG analog was coupled to a protease-specific peptide. After the cleavage of peptide moiety by PSMA in the extracellular space, lipophilic and active TG analog reaches into the cell membranes and inhibits SERCA (Denmeade et al., 2012) . Phase 2 trials of mipsagargin administrated as an intravenous infusion in patients with hepatocellular carcinoma as a second-line therapy following sorafenib (NCT01777594), recurrent or progressive glioblastoma (NCT02067156) or clear cell renal cell carcinoma that J. Rautio et al. European Journal of Pharmaceutical Sciences 109 (2017) 146-161 expresses PSMA has been completed (NCT02607553). Evofosfamide (TH-302) is cancer-targeted hypoxia-activated prodrug (HAP) designed to undergo site-selective bioconversion at the target site. It is a 2-nitroimidazole HAP of bromo-isophosphoramide mustard (Br-IPM) (Duan et al., 2008) . One-electron reductases (e.g. cytochrome P450 reductase) can reduce evofosfamide to its radical anion (Scheme 4). Under hypoxic conditions, an active metabolite Br-IPM is generated after fragmentation of its radical anion intermediate. Evofosfamide failed to show efficacy in phase 3 trials against metastatic pancreatic cancer (NCT01746979) and soft tissue sarcoma (NCT01440088). However, phase 2 trial in recurrent high-grade astrocytoma following bevacizumab has been completed (NCT01403610) and evofosfamide will enter phase 2 trials (recruiting participants) where it will be administered as intravenous infusion against glioma in combination with bevacizumab (NCT02342379) and in combination with sunitinib in neuroendocrine pancreatic tumors (NCT02402062).
Prodrug for prolonged duration of action
TransCon hGH is a sustained-release prodrug of human growth hormone (hGH). The prodrug consists of hGH bound to a methoxypolyethylene glycol (mPEG) carrier through a proprietary Transcon linker (Fig. 13) . GH is released from the mPEG-carrier over a one-week period based on temperature and physiological pH via auto-hydrolysis of the linker (Hoybye et al., 2017) . The carrier protects GH from receptor binding and excretion until it is released. Phase 3 trial for the once a week administrated subcutaneous injection of TransCon compared to daily hGH is ongoing (recruiting participants) in children with growth hormone deficiency (NCT02781727).
Conclusion
Last few years have introduced several new prodrugs to the market. In addition, a glimpse of the pipeline reveals a number of prodrugs undergoing clinical trials, many of them likely crossing the approval threshold in the near future. We hope that this review have raised interest and awareness of the potential of using prodrugs in drug discovery and development projects. 
